Aberdeen Group
EWTX icon

Aberdeen Group’s Edgewise Therapeutics EWTX Stock Holding History

Aberdeen Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26M Buy
826,059
+4,119
+0.5% +$119K 0.04% 341
2025
Q4 		$20.4M Buy
821,940
+202,062
+33% +$4.06M 0.03% 425
2025
Q3 		$10.1M Buy
619,878
+176,559
+40% +$2.5M 0.02% 603
2025
Q2 		$5.81M Buy
443,319
+130,294
+42% +$1.88M 0.01% 684
2025
Q1 		$6.89M Buy
313,025
+134,982
+76% +$3.54M 0.01% 641
2024
Q4 		$4.75M Sell
178,043
-78,602
-31% -$2.5M 0.01% 656
2024
Q3 		$6.85M Buy
+256,645
New +$5.11M 0.01% 596
2024
Q1 		– Sell
-150,418
Closed -$1.65M – 957
2023
Q4 		$1.65M Buy
+150,418
New +$1.06M ﹤0.01% 788

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aberdeen Group's EWTX Position: Q1 2026 in Review

Aberdeen Group increased its Edgewise Therapeutics (EWTX) stake by 0.5% in Q1 2026, buying an estimated $119K and bringing the position to 826,059 shares worth $26M. The position accounts for 0.04% of the portfolio, ranked #341.

Aberdeen Group first reported a position in EWTX in Q4 2023 and has held it in 8 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Aberdeen Group held 826,059 shares of Edgewise Therapeutics worth $26M as of Q1 2026.
  • Aberdeen Group bought 4,119 Edgewise Therapeutics shares in Q1 2026, an estimated $119K.
  • Edgewise Therapeutics made up 0.04% of Aberdeen Group's portfolio in Q1 2026, its #341 holding.
  • Aberdeen Group first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.